Rapid Antimicrobial Susceptibility Testing (AST) using BacterioScan’s 216R Decreases Time for Determining AST by 75%.
St. Louis, MO - December 17, 2014 – BacterioScan Inc. announced the publication of data from a collaboration with the Laboratory Preparedness and Response Branch of the Centers for Disease Control and Prevention (CDC, Atlanta, GA) on Rapid Antimicrobial Susceptibility Testing (AST) with National Allergy and Infectious Disease (NIAID) category A and B pathogens. Data will be presented during the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, D.C. The study examined the use of BacterioScan’s instrument for use to rapidly detect and preform AST on a myriad of bacteria types, including “biothreat” pathogens such as Bacillus anthracis and Yersinia pestis, and concluded that the BacterioScan system can decrease the time to result by 75%.
The company’s product (Model 216R) provides rapid detection and quantification of bacteria and can reduce the time to detect antibiotic resistance from 30+ hours to less than two hours for some common pathogens. Additional research results have been submitted for publication in 2015.
As reported by the President’s Council of Advisors on Science and Technology (PCAST, September 2014), “the effective use and stewardship of antibiotics would be substantially advanced by the widespread use of rapid diagnostics that could provide accurate and timely information on the infecting pathogen, including its resistance profile.”
“Combating antibiotic resistance is an urgent challenge in healthcare, and faster diagnostic technologies are critically needed”, said Dana Marshall, BacterioScan’s President. “We believe that the BacterioScan technology offers the potential for a highly sensitive, yet compact, affordable, and reliable platform for rapid antibiotic resistance detection to help in this fight”.
About BacterioScan Inc.
BacterioScan Inc. is an in-vitro diagnostics (IVD) company based in St. Louis focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan instruments can rapidly detect infection, classify the organism by type and size, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held corporation, with operations in St Louis Missouri, and Israel.
Help employers find you! Check out all the jobs and post your resume.
St. Louis, MO - December 17, 2014 – BacterioScan Inc. announced the publication of data from a collaboration with the Laboratory Preparedness and Response Branch of the Centers for Disease Control and Prevention (CDC, Atlanta, GA) on Rapid Antimicrobial Susceptibility Testing (AST) with National Allergy and Infectious Disease (NIAID) category A and B pathogens. Data will be presented during the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, D.C. The study examined the use of BacterioScan’s instrument for use to rapidly detect and preform AST on a myriad of bacteria types, including “biothreat” pathogens such as Bacillus anthracis and Yersinia pestis, and concluded that the BacterioScan system can decrease the time to result by 75%.
The company’s product (Model 216R) provides rapid detection and quantification of bacteria and can reduce the time to detect antibiotic resistance from 30+ hours to less than two hours for some common pathogens. Additional research results have been submitted for publication in 2015.
As reported by the President’s Council of Advisors on Science and Technology (PCAST, September 2014), “the effective use and stewardship of antibiotics would be substantially advanced by the widespread use of rapid diagnostics that could provide accurate and timely information on the infecting pathogen, including its resistance profile.”
“Combating antibiotic resistance is an urgent challenge in healthcare, and faster diagnostic technologies are critically needed”, said Dana Marshall, BacterioScan’s President. “We believe that the BacterioScan technology offers the potential for a highly sensitive, yet compact, affordable, and reliable platform for rapid antibiotic resistance detection to help in this fight”.
About BacterioScan Inc.
BacterioScan Inc. is an in-vitro diagnostics (IVD) company based in St. Louis focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan instruments can rapidly detect infection, classify the organism by type and size, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held corporation, with operations in St Louis Missouri, and Israel.
Help employers find you! Check out all the jobs and post your resume.
